DiagnosTear Seals Deal to Commercialize Eye Imaging Platform
DiagnosTear (DTR.CN) on Tuesday said it reached a deal to commercialize the Clarify eye imaging platform developed by Sheba Impact and Tel Aviv University.Clarify enables AI-driven blood analysis through a simple eye scan, eliminating the need for needles and traditional blood draws. If successfully developed and clinically validated, Clarify could provide instant measurement of critical blood markers such as red blood cells, hemoglobin and potentially white blood cells and other biomarkers through a quick, needle-free eye scan, a statement said.Under the agreement, DiagnosTear receives exclusive global rights to develop, manufacture, and commercialize Clarify-based products. The licensors retain ownership of the underlying intellectual property.Key terms include a 3% royalty on annual net sales up to US$20 million."This agreement secures exclusive access to a technology that could redefine how blood diagnostics are performed at some selected common clinical scenarios," said Dr. Shimon Gross, DiagnosTear chief executive.DiagnosTear shares closed unchanged at $0.30, on the Canadian Securities Exchange.
